Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw unusually-high trading volume on Monday . Approximately 7,007 shares traded hands during mid-day trading, an increase of 41% from the previous session’s volume of 4,973 shares.The stock last traded at $17.26 and had previously closed at $17.12.

Analyst Upgrades and Downgrades

AAPG has been the topic of several analyst reports. B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target on the stock. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company. Finally, BTIG Research reissued a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Stock Performance

The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The company’s fifty day moving average price is $21.10 and its two-hundred day moving average price is $24.16.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million for the quarter. Analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -0.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. UBS Group AG boosted its holdings in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in Ascentage Pharma Group International during the second quarter worth about $391,000. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth about $383,000. Finally, XY Capital Ltd lifted its stake in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares in the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.